Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

Patients Receiving Every Four-Week Subcutaneous Golimumab Also Experienced

Improvements in Physical Function and Disease Activity

PARIS, June 11 /PRNewswire/ -- Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg and weekly methotrexate (MTX) experienced significant improvements in the signs and symptoms of rheumatoid arthritis (RA) as well as in physical function and disease activity, with some patients achieving remission as measured by Disease Activity Score (DAS28). Findings from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies showed the efficacy of golimumab in two important populations - MTX-naive patients and patients with active RA despite ongoing treatment with MTX. These data were presented at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an anti-tumor necrosis factor (TNF)-alpha biologic therapy with ongoing studies for the treatment of RA, psoriatic arthritis and ankylosing spondylitis.

In the study, GOlimumab FOR subjects With Active RA Despite MTX (GO-FORWARD), both the 50 mg and 100 mg doses of golimumab were studied in patients whose disease was active despite ongoing treatment with MTX. At week 14, 55 percent of patients receiving golimumab 50 mg plus MTX and 56 percent receiving golimumab 100 mg plus MTX achieved at least 20 percent improvement in signs and symptoms of RA (ACR 20), compared to 33 percent of patients receiving placebo and MTX (p<0.01 and p<0.001, respectively). Improvements were seen as early as first clinical assessment, which was four weeks after the first golimumab injection, and generally continued to improve over time.

"The data in this study demonstrate that golimumab is beneficial in improving numerous disease parameters, including in
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Pomerantz LLP is investigating ... ("PDL BioPharma" or the "Company") (NASDAQ: PDLI).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On September 17, 2014, the Company ...
(Date:9/17/2014)... 17, 2014  Rebiotix Inc. announced this morning that results ... candidate, RBX2660 (microbiota suspension) will be presented in two posters ... Philadelphia from October 8-12. ... poster session on Thursday, October 9, 2014: Poster: ... 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... , Sept. 17, 2014  Bayer HealthCare will present ... Foundation,s 66 th Annual Meeting, which takes place ... The data, which will be shared through poster presentations, ... patient care. Data will be presented in a scientific ... treatment modalities in hemophilia A patients, Bayer is maintaining ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4
...   , Strategic collaboration with Ipsen for marketing ... Nordics and the US , Photocure to commercialise ... Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on ... of a new commercial strategy for Hexvix, its flagship product ...
... Luminex Corporation (NASDAQ: LMNX ), today ... its annual European multiplexing technology symposium, September 28-29, 2011, ... feature scientific sessions, workshops, discussion groups, exhibitions and networking ... who are performing groundbreaking work in clinical diagnostics and ...
Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 4
(Date:9/17/2014)... 2014 People who struggle to distinguish between ... http://www.perwickstrom.com and get the answer by reading Per ... out, is that a business plan and a business strategy ... commented Per Wickstrom. “The way I view it is that ... strategy which is part two.” , According to the ...
(Date:9/17/2014)... damage to the ends of chromosomes could hold the key ... form of skin cancer according to new research from ... an important new genetic risk factor for melanoma. , It ... strongest indicators of those most at risk of developing melanoma. ... sun, as they burn more easily. , It now appears ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 North Central ... recently granted several awards for their top-notch services. The ... experience, orthopedic care and GYN surgery. , Hospital-wide, North ... Excellence Award™. They have received this award for two ... the top 5 percent in the nation for Patient ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
(Date:9/17/2014)... News) -- Positive messages about the health benefits of ... a new study suggests. Although smokers who think ... about the harmful effects of smoking, researchers found smokers ... more from "gain-framed," or positive, messages about how quitting ... using a mix of both types of messages might ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... Washingtonian ... ... was identified as a "Top Therapist" in the July 2009 issue of Washingtonian ... playing in the Washington, DC, area for more than four decades thanks to features like ...
... ... supplier of industrial and technical parts and free CAD images to engineers, ... customers. John Carrier, the company,s President, says the new ReidSupply.com is all about ... on marketing. The new site takes the customer exactly where they want to ...
... LONDON, July 7 Frost & Sullivan has conferred ... (VWS). The "2008 Frost & Sullivan European Pharmaceutical Water ... VWS for its successful strategies that have enabled it ... process water and wastewater solution providers for the pharmaceutical ...
... OAK BROOK, Ill. (July 7, 2009) Using magnetic resonance ... and accurately locate lesions prior to surgery, according to a ... . "Pelvic MRI at 3 Tesla is a ... said the study,s lead author, Nathalie Hottat, M.D., from the ...
... SMOKING CESSATION MAY PROVIDE IMMEDIATE BENEFIT TO HEART ... provides immediate benefits to patients. Researchers from the ... examined specific inflammatory biomarkers associated with cardiovascular disease ... cessation process. Results showed that smoking cessation resulted ...
... Sonitus Medical, Inc., a medical device company developing the ... sound via the teeth, today announced the acceptance for ... SoundBite(TM) hearing system. The article, featuring a preliminary evaluation ... in an upcoming issue of the esteemed Otology ...
Cached Medicine News:Health News:Karen J. Osterle Recognized as a Top Psychotherapist in Washingtonian Magazine 2Health News:Customers Design Reid Supply's New Web Site 2Health News:Customers Design Reid Supply's New Web Site 3Health News:Customers Design Reid Supply's New Web Site 4Health News:Customers Design Reid Supply's New Web Site 5Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 2Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 3Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 4Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 5Health News:MRI accurately depicts deep endometriosis 2Health News:News briefs from the July issue of CHEST 2Health News:SoundBite(TM) Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology & Neurotology Journal 2Health News:SoundBite(TM) Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology & Neurotology Journal 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: